Inclusion Criteria
	Albumin >= 2.5 mg/dL
	International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
	Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
	Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
	Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year 
	Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy

Exclusion Criteria
	Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to cycle 1, day 1 
	Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs) 
	Current or recent (within 10 calendar days prior to cycle 1, day 1) use of dipyridamole, ticlopidine, clopidogrel, or cilostazol 
	Warfarin is not permitted; prophylactic or therapeutic use of low molecular-weight heparin (e.g., enoxaparin), direct thrombin inhibitors or factor Xa inhibitors (direct or indirect) are permitted are permitted
	History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to cycle 1, day 1 
	Serious, non-healing or dehiscing wound 
	Proteinuria > 2.0 g of protein in a 24-hour urine collection; all patients with 2 protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection for protein 
	Has a history of (non-infectious) pneumonitis that required steroids, current pneumonitis or evidence of interstitial lung disease
